MTOR and cancer: It has been shown recently that mTOR inhibitor rapamycin decreases lactate production in cancer cell lines regardless of normoxia or hypoxia [51, 52], which may also extend our further anticancer investigation to target aerobic glycolytic adaptation to oncolytic viruses by mTOR inhibitors.